ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has landed an additional contract worth US$1.2mln with a "large-scale pharma services customer".
Its Parsortix liquid biopsy technology will be used to help assess disease progression in certain solid tumours that cannot be surgically removed as part of a phase Ib drug trial.
"We have previously indicated that we expect repeat business from our pharma services customers,” said ANGLE chief executive Andrew Newland.
“We believe that the Parsortix liquid biopsy has particular advantages in capturing intact cancer cells, including mesenchymal cells and clusters, and provides the opportunity for longitudinal testing in a clinical setting. This is not possible with tissue biopsy.”